OCULAR THERAPEUTIX INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
OCUL$6.60+2.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · · December 31, | ||||||
| · 2024 · 2023 | ||||||
| Assets · · | ||||||
| Current assets: · · · | ||||||
| Cash and cash equivalents | | $392,102 | | $195,807 | ||
| Accounts receivable, net | | 32,388 | | 26,179 | ||
| Inventory | | 3,040 | | 2,305 | ||
| Restricted cash | | | — | | | 150 |
| Prepaid expenses and other current assets | | 13,457 | | 7,794 | ||
| Total current assets | | 440,987 | | 232,235 | ||
| Property and equipment, net | | 9,389 | | 11,739 | ||
| Restricted cash | | 1,614 | | 1,614 | ||
| Operating lease assets | | | 5,945 | | | 6,472 |
| Total assets | | $457,935 | | $252,060 | ||
| Liabilities and Stockholders’ Equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $4,176 | | $4,389 | ||
| Accrued expenses and other current liabilities | | 35,117 | | 28,666 | ||
| Deferred revenue | | 128 | | 255 | ||
| Operating lease liabilities | | | 1,933 | | | 1,586 |
| Total current liabilities | | 41,354 | | 34,896 | ||
| Other liabilities: | | | | | ||
| Operating lease liabilities, net of current portion | | | 5,345 | | | 6,878 |
| Derivative liabilities | | | 13,246 | | | 29,987 |
| Deferred revenue, net of current portion | | | 14,000 | | | 14,135 |
| Notes payable, net | | 68,505 | | 65,787 | ||
| Other non-current liabilities | | | 141 | | | 108 |
| Convertible Notes, net | | — | | 9,138 | ||
| Total liabilities | | 142,591 | | 160,929 | ||
| Commitments and contingencies (Note 18) | | | | | ||
| Stockholders’ equity: | | | | | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at December 31, 2024 and December 31, 2023, respectively | | — | | — | ||
| Common stock, $0.0001 par value; 400,000,000 and 200,000,000 shares authorized and 157,749,490 and 114,963,193 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | | 16 | | 12 | ||
| Additional paid-in capital | | 1,206,412 | | 788,697 | ||
| Accumulated deficit | | (891,084) | | (697,578) | ||
| Total stockholders’ equity | | 315,344 | | 91,131 | ||
| Total liabilities and stockholders’ equity | | $457,935 | | $252,060 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.